UBS Maintains a 'Buy' on AmerisourceBergen (ABC); Lower F2013-14 EPS For Generics + Medco
ABC Hot Sheet
Rating Summary:5 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 18 | Down: 7 | New: 23
UBS maintains a 'Buy' on AmerisourceBergen (NYSE: ABC) price target lowered from $47 to $44.
UBS analyst says, "Even though it is still unclear whether or not the Express Scripts (Nasdaq: ESRX) / Medco (NYSE: MHS) merger will be completed, we have decided to take a conservative stance and model our ABC projections with the assumption that the merger will be completed, and that ABC will ultimately lose the Medco drug distribution business when the current contract expires in March 2013. But we do note $0.20-0.25 of EPS upside pot’l for ABC if they are able to capture the entire contract."
"We lower FY13 EPS from $3.20 to $3.05 with subtraction of Medco, but we are also tweaking down our EPS estimates to better account for the lack of material new ‘exclusivity’ generic intro ductions in F2013, coupled with the likely generic deflation expected on many of the key ‘exclusivity’ generic products launched in ABC’s F2012 that will become ‘multi-source’ in ABC’s F2013."
For an analyst ratings summary and ratings history on AmerisourceBergen click here. For more ratings news on AmerisourceBergen click here.
Shares of AmerisourceBergen closed at $38.84 yesterday, with a 52 week range of $34.33-$43.47.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
UBS analyst says, "Even though it is still unclear whether or not the Express Scripts (Nasdaq: ESRX) / Medco (NYSE: MHS) merger will be completed, we have decided to take a conservative stance and model our ABC projections with the assumption that the merger will be completed, and that ABC will ultimately lose the Medco drug distribution business when the current contract expires in March 2013. But we do note $0.20-0.25 of EPS upside pot’l for ABC if they are able to capture the entire contract."
"We lower FY13 EPS from $3.20 to $3.05 with subtraction of Medco, but we are also tweaking down our EPS estimates to better account for the lack of material new ‘exclusivity’ generic intro ductions in F2013, coupled with the likely generic deflation expected on many of the key ‘exclusivity’ generic products launched in ABC’s F2012 that will become ‘multi-source’ in ABC’s F2013."
For an analyst ratings summary and ratings history on AmerisourceBergen click here. For more ratings news on AmerisourceBergen click here.
Shares of AmerisourceBergen closed at $38.84 yesterday, with a 52 week range of $34.33-$43.47.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- Needham & Company Reiterates a 'Buy' on NetApp (NTAP); Solid 4Q Overshadowed by Conservative 1Q
- Barclays Adjusting Estimates on Coca-Cola (KO); Seeing A More Well-Balanced Portfolio
- Nomura Securities Raises PT and Estimates on PetSmart (PETM) After Good Q1
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
